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OBJECTIVEdMalabsorptive bariatric surgery (biliopancreatic diversion and biliointestinal
bypass [BIBP]) reduces serum cholesterol levels more than restrictive surgery (adjustable gastric
banding [AGB]), and this is thought to be due to greater weight loss. Our aim was to evaluate the
changes of cholesterol metabolism induced by malabsorptive and restrictive surgery indepen-
dent of weight loss.
RESEARCHDESIGNANDMETHODSdIn a nonrandomized, self-selected, unblinded,
active-comparator, bicenter, 6-month study, glucose metabolism (blood glucose and serum in-
sulin levels and homeostasis model assessment of insulin resistance [HOMA-IR] index) and
cholesterol metabolism (absorption: serum campesterol and sitosterol levels; synthesis: serum
lathosterol levels; catabolism: rate of appearance and serum concentrations of serum 7-a- and
serum 27-OH-cholesterol after infusions of deuterated 7-a- and 27-OH-cholesterol in sequence)
were assessed in grade 3 obesity subjects undergoing BIBP (n = 10) and AGB (n = 10). Evaluations
were performed before and 6 months after surgery.
RESULTSdSubjects had similar values at baseline. Weight loss was similar in the two groups
of subjects, and blood glucose, insulin levels, HOMA-IR, and triglycerides decreased in a similar
way. In contrast, serum cholesterol, LDL cholesterol, non-HDL cholesterol, serum sitosterol, and
campesterol levels decreased and lathosterol levels increased only in BIBP subjects, not in AGB
subjects. A signiﬁcant increase in 7-a-OH-cholesterol occurred only with BIBP; serum 27-OH-
cholesterol decreased in both groups.
CONCLUSIONSdMalabsorptive surgery speciﬁcally affects cholesterol levels, independent
of weight loss and independent of glucose metabolism and insulin resistance. Decreased sterol
absorption leads to decreased cholesterol and LDL cholesterol levels, accompanied by enhanced
cholesterol synthesis and enhanced cholesterol catabolism. Compared with AGB, BIBP provides
greater cholesterol lowering.
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The epidemic of obesity has led to adramatic increase of the number ofbariatric procedures performed
worldwide (1). Bariatric procedures are com-
monly divided into restrictive (adjustable
gastric banding [AGB], vertical-banded
gastroplasty, and sleeve gastrectomy),
malabsorptive (biliopancreatic diversion
[BPD] and biliointestinal bypass [BIBP]),
andmixed procedures (gastric bypass and
Roux-en-Y gastric bypass [RYGB]) (1–3).
Malabsorptive procedures are associated
with a far greater weight loss than restric-
tive procedures and with quicker meta-
bolic changes, namely drop of blood
glucose levels (2).
Malabsorptive surgery also reduces
serum cholesterol levels; in fact, it was
originally intended for the treatment of
hyperlipidemias and was highly effective
even in patients without morbid obesity
(the Program on Surgical Control of Hy-
perlipidemias study) (4). Malabsorptive
surgery is more effective than restrictive
surgery in reducing cholesterol levels (5),
and our group has shown that by 1 year
after surgery, both BPD and BIBP reduce
cholesterol levels more than AGB, and
this effect is associated with greater
weight loss (6,7). In addition, the choles-
terol decrease correlates with loss of fat
mass (7). Therefore, the main factor con-
sidered responsible for decreased chole-
sterol levels is weight loss.
However, up to 6months, weight loss
is similar with BIBP and AGB (7), and this
led us to hypothesize that it was possible
to study cholesterol absorption, as well as
other aspects of cholesterol metabolism,
independently of weight loss.
Therefore, we planned a study on the
intestinal absorption of sterols, choles-
terol synthesis, and cholesterol catabo-
lism via synthesis of biliary acids in obese




and AGB) is routinely performed at the
obesity centers of the institutions partici-
pating in this study. Patients are eligible
for bariatric surgery if they meet the
following criteria: 18–65 years of age
and a BMI .40.0 kg/m2 alone or a BMI
.35.0 kg/m2 in the presence of comor-
bidities, plus a history of at least two pre-
vious dietary attempts followed by a
relapse. The clinical protocol includes a
medical history, physical and biochemi-
cal evaluation, and a psychological and
psychiatric evaluation performed to verify
indications, contraindications, and safety
of surgical procedures (3,8). For all sub-
jects undergoing BIBP or AGB, after sur-
gery the suggested diet is 970 and 1,090
kcal per day in women and men, respec-
tively; iron is supplemented on the basis
of blood examinations performed during
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the 2nd month. The diet includes 48%
carbohydrates (starch or bread), 33%
proteins (fat-free parts of different ani-
mals and ﬁshes), and 19% lipids (olive
oil); sweets, cakes, sweetened drinks, al-
cohol, and animal lipids are forbidden. All
foods have to be cooked without oil, but-
ter, or other lipids; in addition, BIBP
patients receive vitamin D3 at discharge
(two administrations per month), vitamin
B12 (5,000 units once per month), and
oral antidiarrheal drugs (diphenoxylate
or loperamide) when there are.10 bowel
movements per day (3,8).
Study protocol
This was a nonrandomized, self-selected,
unblinded, active-comparator, bicenter,
6-month study. The whole protocol was
approved by the local ethics committees.
The subjects, all Caucasian, were in-
formed about the nature and aims of the
cholesterol metabolism evaluation proto-
col, and they signed a written informed
consent. The choice of surgical procedure
was made by the patient together with the
surgeon, after a full explanation of the
risks and possible beneﬁts of each pro-
cedure. In total, 10 subjects underwent
BIBP and 10 underwent AGB.
After all interventions, subjects were
re-evaluated by a dietitian and physician
at 2-week intervals for 2 months and then
monthly for up to 6months, as previously
described (3,8). At baseline and 6 months
after surgical procedures, the subjects
were studied in the early morning in a re-
cumbent position and after an overnight
fast. Height and weight were measured to
the nearest 0.5 cm and 0.1 kg, respec-
tively.
Blood drawing and isotope infusion
A venous line was used for blood sam-
pling, and another venous line on the
opposite arm was used for infusions. Both
venous lines were kept patent by a slow
0.9% NaCl saline drip.
After a blood drawing for metabolites,
sequential infusions of deuterated oxy-
sterols were performed between 9:00 A.M.
and 2:00 P.M., according to a previously
published protocol (9). Serum samples
were obtained from blood collected dur-
ing the sequential infusions of the two
hydroxysterols at 0, 60, 80, 100, and
120 min. Plant sterols (campesterol and
sitosterol) were measured as biomarkers
of cholesterol absorption, and lathosterol
as a marker of cholesterol synthesis (10).
7-a-OH-cholesterol and27-OH-cholesterol
are markers of bile acid metabolism, the
former of direct intrahepatic metabolism
and the latter of mainly extrahepatic ca-
tabolism (9); bile acid synthesis accounts
for .95% of cholesterol catabolism per
day (9).
Laboratory assays
Plasma glucose was measured by the
glucose oxidation method (YSI, Inc., Yel-
low Springs, OH). Serum insulin was
assayed by microparticle enzyme immu-
noassay (Abbott Laboratories, Pasadena,
CA) (8). Total cholesterol, HDL chole-
sterol, and triglyceride levels were assayed
by automated enzymatic methods
(Roche, Basel, Switzerland). LDL choles-
terol was calculated using the Friedewald
equation (11). Non-HDL cholesterol was
calculated as total cholesterol – HDL
cholesterol (12). The homeostasis model
assessment of insulin resistance [HOMA-
IR] index was calculated as blood glucose
(mmol/L) 3 insulin (mU/mL) 3 22.521
(13).
Quantitative evaluation of lathos-
terol, campesterol, and b-sitosterol in se-
rum was performed by a gas-liquid
chromatography/mass spectrometry
(GC/MS)–based technique as previously
described (14). For determination of hy-
droxysterol serum concentrations, after
the addition of 250 ng 19-OH-cholesterol
as internal standard to 0.2 mL serum, sam-
ples were hydrolyzed and extracted (15).
The organic phase was evaporated to dry-
ness under a streamof nitrogen andpuriﬁed
by solid-phase extraction. The fraction
containing the hydroxysterols was dried
and treated with trimethylsilylimidazole:
piperidine (1:1) before analysis by GC/
MS.
Deuterated oxysterol infusions
Deuterated (d6) 7-a-OH-cholesterol was
obtained by chemical synthesis from deu-
terated (d6) cholesterol, according to pre-
viously described methods (15), and
deuterated 27-OH-cholesterol was pre-
pared by synthesis from kryptogenin, us-
ing the Clemmensen reduction method,
as previously described (16). Homoge-
neous suspensions of the sterols in 5%
human albumin were prepared on the
same day of the infusion experiment (ﬁnal
concentration of 3 and 6 mg/mL of deu-
terated 7-a- and 27-OH-cholesterol, re-
spectively) and ﬁltered through a
0.22-mm Millipore membrane immedi-
ately before infusion, under a laminar
ﬂow hood (14). Serum samples, obtained
from blood collected during the sequen-
tial infusions of the two hydroxysterols
(see above), were analyzed for deuterium
enrichment of 7-a- and 27-OH-cholesterol
using GC/MS on extracted oxysterols as
previously reported (14). The in vivo rate
of appearance of the two hydroxysterols
was calculated as milligrams per hour
from the deuterated/natural sterol ion ra-
tio and infusion rate using the equation
described for the steady state by Duane
and Javitt (17).
Table 1dClinical and metabolic details of obese subjects in the study, divided by surgical
technique
BIBP (n = 10) AGB (n = 10)
Age 45.1 6 1.59 47.5 6 2.04
Sex (male/female) 3/7 3/7
BMI (kg/m2) 45.9 6 0.56 46.2 6 2.05
Blood glucose (mg/dL) 96.6 6 3.72 112.0 6 12.05
Insulin (mU/mL) 16.9 6 1.11 18.7 6 2.18
HOMA-IR (mU/mL z mmol/22.5) 4.0 6 0.29 5.3 6 0.89
Serum cholesterol (mg/dL) 192.2 6 3.44 199.7 6 7.69
Serum LDL cholesterol (mg/dL) 116.8 6 1.39 121.5 6 4.19
Serum HDL cholesterol (mg/dL) 52.8 6 2.28 53.1 6 6.28
Serum non-HDL cholesterol (mg/dL) 139.5 6 3.58 146.6 6 3.74
Serum triglycerides (mg/dL) 143.1 6 14.71 160.7 6 19.05
Serum sitosterol (mg/dL) 382.3 6 22.38 331.5 6 69.31
Serum campesterol (mg/dL) 230.4 6 14.62 175.2 6 46.28
Serum lathosterol (mg/dL) 179.8 6 8.23 248.4 6 34.31
7-a-OH-cholesterol (mg/h) 2.3 6 0.22 2.3 6 0.31
7-a-OH-cholesterol (mg/dL) 5.6 6 0.31 5.5 6 0.82
27-OH-cholesterol (mg/h) 4.9 6 0.42 6.1 6 0.53
27-OH-cholesterol (mg/dL) 11.3 6 1.65 13.9 6 1.73
Data presented as mean 6 SE or absolute numbers. No signiﬁcant differences were found.
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Statistical analysis
Data were expressed as means 6 SE. In-
tergroup comparisons and within-group
differences were performed by Student
t test for unpaired and paired data, respec-
tively; changes before and after 6 months
between the two surgical procedures were
also compared by Student t test for un-
paired data. All statistical analyses were
performed by Statview software for Mac-
intosh. P , 0.05 was considered statisti-
cally signiﬁcant.
Sample size and power calculation
The sample size allowed for the detection
of a 50% difference or more between
subjects undergoing restrictive or malab-
sorptive procedures in total cholesterol
decrease, with a type 1 error of 0.05 and a
power of 0.8. Assuming a difference in
cholesterol decrease of 50 mg/dL with an
SD of 10 mg/dL (2,5–7), and a rate of 1:1
between the two groups of subjects, 16
subjects were required. Assuming 15%
would be noncompleters, 20 subjects
were included.
RESULTSdTable 1 shows the clinical
and metabolic data of obese subjects en-
tering the study; all variables were similar
in the two groups, with no signiﬁcant dif-
ference.
Figure 1 shows that the decrease of
BMI, HOMA-IR, and triglycerides was
similar in the two groups; a small but sig-
niﬁcant decrease was observed in HDL
cholesterol levels in subjects undergoing
BIBP, but with no signiﬁcant difference
from subjects undergoing AGB. Also,
blood glucose and insulin levels de-
creased in a signiﬁcant manner, with no
difference between BIBP and AGB (not
shown). In contrast, total cholesterol
and LDL cholesterol levels were affected
in a different way by BIBP and AGB, with a
clear intergroup difference.
Figure 2 shows that non-HDL chole-
sterol, sitosterol, and campesterol levels
decreased with BIBP, but not with AGB.
Serum lathosterol increased with BIBP,
but not with AGB, with a signiﬁcant dif-
ference between BIBP and AGB.
Figure 3 shows that the rate of ap-
pearance and serum levels of 7-a-OH-
cholesterol increased with BIBP, but not
with AGB, with a signiﬁcant difference
between BIBP and AGB. The rate of ap-
pearance of 27-OH-cholesterol did not
vary with either BIBP or AGB, but the
trend was signiﬁcantly different; the se-
rum levels of 27-OH-cholesterol de-
creased in a similar way with BIBP and
AGB.
CONCLUSIONSdThe aim of this
study was to assess intestinal cholesterol
absorption, cholesterol synthesis, and
cholesterol catabolism in obese subjects
undergoing two different surgical techni-
ques, one based on pure malabsorption
(BIBP) and the other on restriction of the
stomach (AGB). The studies were per-
formed under basal conditions and 6
months later, when the decrease of BMI
was expected to be similar. Although the
decrease of blood glucose, insulin,
HOMA-IR index, and triglycerides was
similar between the two groups, signiﬁ-
cant differences between pre- and post-
surgery cholesterol metabolism appeared
in subjects undergoing BIBP, but not in
subjects undergoing AGB. In particular,
total cholesterol, LDL cholesterol, non-
HDL cholesterol, campesterol, and sitos-
terol decreased, and lathosterol increased,
together with the hepatic cholesterol ca-
tabolism pathway (7-a-OH-cholesterol).
This leads us to speculate that with
malabsorptive surgery, cholesterol ab-
sorption decreases, which is associated
with a clear decrease of LDL cholesterol
(and of non-HDL cholesterol). As a com-
pensation, cholesterol synthesis increases,
and this is associated with enhanced
hepatic catabolism. The increase in
lathosterol, a marker of cholesterol syn-
thesis, would also point to enhanced LDL
receptor activity in the liver, which would
lead to reduced circulating LDL levels.
In contrast, cholesterol absorption is
Figure 1dMetabolic changes induced by BIBP and AGB in grade 3 obesity. Baseline (black
columns) and postsurgery (white columns) values are indicated. Means 6 SE. n = 10 in each
panel. P values on top of columns indicate signiﬁcance of pre- vs. postchange. P values between
columns (two-sided arrows) indicate signiﬁcance of intergroup differences.
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unchanged in restrictive surgery, and LDL
cholesterol shows a small but signiﬁcant
increase, if any. The only effect of purely
restrictive surgery is a decrease in
extrahepatic cholesterol catabolism, paral-
lel with an increase in LDL cholesterol, a
ﬁnding that at present is unexplained.
These data, obtained at 6 months, cannot
be assumed as representative of the full
picture of cholesterol metabolism after-
ward; in any case, these data indicate
that different technical surgical techniques
have a different effect on cholesterol levels,
independent of weight loss.
Diet after surgery does not seem to be
of importance, as differences between
BIBP and AGB were negligible for the fat/
cholesterolcontent; in addition, fat andcho-
lesterol do not affect intestinal absorption
of cholesterol as measured through plant
sterols (10). However, it is noticeable that
the different effects of BIBP and AGB per-
sist for up to 3 or 6 years (2,5–7,18). The
cholesterol reduction that we and others
have reported after BIBP, BPD, or RYGB is
quite a dramatic phenomenon and is likely
due to the major reduction in cholesterol
and bile acid reabsorption in the intestine,
and possibly due to altered regulation of
the feedback mechanisms controlled by
nuclear proteins such as LXR, FXR, and
peroxisome proliferator–activated recep-
tor; these transcriptional factors are in-
volved in bile acid and cholesterol
metabolism in patients undergoing BIBP,
BPD, or RYGB (which cause malabsorp-
tion and also reduce bile reabsorption)
but not AGB (a purely restrictive bariatric
procedure) (19). It is also possible that re-
duced gastric volume and reduced pro-
duction of gastric lipase, as well as
reduced secretion of cholecystokinin
(which physiologically stimulates diges-
tive enzyme secretion such as lipases and
proteases), might result in a marked de-
crease in the hydrolysis of triacylglycerols,
with a reduction of the absorption of free
fatty acids (20). BPD and RYGB include
partial gastric resection, or functional gas-
tric disconnection; therefore, gastric by-
pass and BPD cannot be regarded as
purely restrictive or purely malabsorptive
surgical techniques. Blood glucose and se-
rum insulin levels decreased to a similar
extent with the two techniques, as was the
case for the HOMA-IR index. These data
indicate that changes of cholesterol ab-
sorption, synthesis, and catabolism were
independent of glycemic control, insulin,
and insulin resistance. In conclusion,
compared with AGB, BIBP provides
greater cholesterol lowering.
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lesterol (sitosterol and campesterol) and of cholesterol synthesis (lathosterol) induced by BIBP
and AGB. Baseline (black columns) and postsurgery (white columns) values are indicated.
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niﬁcance of intergroup differences.
Figure 3dRate of appearance (mg/h) and serum levels (mg/dL) of markers of bile acid metab-
olism before and after BIBP and AGB. Baseline (black columns) and postsurgery (white columns)
values are indicated. Means 6 SE. n = 10 in each panel. P values between columns (two-sided
arrows) indicate signiﬁcance of intergroup differences.
1446 DIABETES CARE, VOLUME 36, JUNE 2013 care.diabetesjournals.org
Cholesterol metabolism and bariatric surgery
A.B. designed the study, performed in vivo
studies, analyzed data, contributed to discus-
sion, and wrote the paper. M.D.P. performed
laboratory analysis and contributed to dis-
cussion. A.C. contributed to discussion. A.V.
recruited patients and contributed to discus-
sion. E.M., G.M., and V.P. performed bariatric
surgery and contributed to discussion. F.F.
instructed patients and contributed to dis-
cussion. A.E.P. designed the study, analyzed
data, contributed to discussion, wrote the
paper, and reviewed and edited the manu-
script. A.E.P. is the guarantor of this work and,
as such, had full access to all the data in the
study and takes responsibility for the integrity
of the data and the accuracy of the data anal-
ysis.
References
1. Buchwald H, Oien DM. Metabolic/bariatric
surgery worldwide 2008. Obes Surg 2009;
19:1605–1611
2. Buchwald H, Estok R, Fahrbach K, et al.
Weight and type 2 diabetes after bariatric
surgery: systematic review and meta-
analysis. Am J Med 2009;122:248–256,
e5
3. Doldi SB, Lattuada E, Zappa MA, Pieri G,
Restelli A, Micheletto G. Biliointestinal
bypass: another surgical option. Obes
Surg 1998;8:566–569
4. Buchwald H, Rudser KD, Williams SE,
Michalek VN, Vagasky J, Connett JE.
Overall mortality, incremental life expec-
tancy, and cause of death at 25 years in the
program on the surgical control of the
hyperlipidemias. Ann Surg 2010;251:
1034–1040
5. Buchwald H, Avidor Y, Braunwald E, et al.
Bariatric surgery: a systematic review and
meta-analysis. JAMA 2004;292:1724–
1737
6. Pontiroli AE, Laneri M, Veronelli A, et al.
Biliary pancreatic diversion and laparo-
scopic adjustable gastric banding in mor-
bid obesity: their long-term effects on
metabolic syndrome and on cardiovascu-
lar parameters. Cardiovasc Diabetol 2009;
8:37
7. Frige’ F, Laneri M, Veronelli A, et al.
Bariatric surgery in obesity: changes of
glucose and lipid metabolism correlate
with changes of fat mass. Nutr Metab
Cardiovasc Dis 2009;19:198–204
8. Pontiroli AE, Pizzocri P, Librenti MC, et al.
Laparoscopic adjustable gastric banding
for the treatment of morbid (grade 3)
obesity and its metabolic complications:
a three-year study. J Clin Endocrinol
Metab 2002;87:3555–3561
9. Del Puppo M, Crosignani A, Longo M,
et al. A minimally invasive technique for
the evaluation of the regulatory steps of
the two major pathways of bile acid syn-
thesis. Clin Chim Acta 2005;355:23–31
10. Nissinen MJ, Gylling H, Miettinen TA.
Effects of dietary cholesterol and fat on
serum non-cholesterol sterols according
to different apolipoprotein E subgroups
among healthy men. Br J Nutr 2008;100:
373–379
11. Friedewald WT, Levy RI, Fredrickson DS.
Estimation of the concentration of low-
density lipoprotein cholesterol in plasma,
without use of the preparative ultracen-
trifuge. Clin Chem 1972;18:499–502
12. Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol
in Adults. Executive Summary of the
Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel
on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults
(Adult Treatment Panel III). JAMA 2001;
285:2486–2497
13. Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF, Turner RC. Ho-
meostasis model assessment: insulin re-
sistance and beta-cell function from
fasting plasma glucose and insulin con-
centrations inman. Diabetologia 1985;28:
412–419
14. Del Puppo M, Kienle MG, Petroni
ML, Crosignani A, Podda M. Serum 27-
hydroxycholesterol in patients with pri-
mary biliary cirrhosis suggests alteration
of cholesterol catabolism to bile acids via
the acidic pathway. J Lipid Res 1998;39:
2477–2482
15. Ciuffreda P, Casati S, Alessandrini L,
Terraneo G, Santaniello E. Synthesis of
deuterated isotopomers of 7a- and
(25R,S)-26-hydroxycholesterol, internal
standards for in vivo determination of the
two biosynthetic pathways of bile acids.
Steroids 2003;68:733–738
16. Javitt NB, Kok E, Lloyd J, Benscath A,
Field FH. Cholest-5-ene-3 beta, 26-diol:
synthesis and biomedical use of a deu-
terated compound. Biomed Mass Spec-
trom 1982;9:61–63
17. Duane WC, Javitt NB. 27-hydrox-
ycholesterol: production rates in normal
human subjects. J Lipid Res 1999;40:
1194–1199
18. Corradini SG, Eramo A, Lubrano C, et al.
Comparison of changes in lipid proﬁle
after bilio-intestinal bypass and gastric
banding in patients with morbid obesity.
Obes Surg 2005;15:367–377
19. Repa JJ, Mangelsdorf DJ. Nuclear receptor
regulation of cholesterol and bile acid
metabolism. Curr Opin Biotechnol 1999;
10:557–563
20. Bays HE. Current and investigational an-
tiobesity agents and obesity therapeutic
treatment targets. Obes Res 2004;12:
1197–1211
care.diabetesjournals.org DIABETES CARE, VOLUME 36, JUNE 2013 1447
Benetti and Associates
